Morphic Raises $51.5M to Develop Next-Generation Integrin Therapies for IBD, Other Diseases

Morphic Raises $51.5M to Develop Next-Generation Integrin Therapies for IBD, Other Diseases
Morphic Therapeutic announced that it has raised $51.5 million through Series A financing to advance products and bring them into clinical testing. The Massachusetts-based company specializes in oral integrins. SR One and Pfizer Venture Investments led the round, with participation from other investors that included Omega Funds and AbbVie Ventures. The company was founded in 2015 on work from the lab of Tim Springer, a professor

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *